Five Prime Therapeutics Stock Company Profile

Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. The company’s FP-1039/GSK3052230 is in Phase Ib clinical trials to treat patients with lung cancer and malignant pleural mesothelioma. It has license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company, and UCB Pharma S.A.; and license agreement with Galaxy Biotech, LLC, INBRX 110 LP, The Regents of the University of California, BioWa, Inc., Board of Trustees of the Leland Stanford Junior University, Lonza Sales AG, and National Research Council of Canada. The company was founded in 2001 and is headquartered in South San Francisco, California.